Juliet & Romeo by
David & Kelly Gerstenhaber

Although
the emotions we felt upon our golden retriever’s diagnosis
of lymphoma are practically beyond verbal description, the
experience can best be described as devastating, characterized
by emotions including sorrow, anger, and grief. It seemed
unbelievable that the light of our life and our home was
faced with a life-threatening illness that most likely would
take her from us, particularly as we are two educated people
who were confronted with the very concept of animal cancer
for the very first time. However, our initial profound sense
of helplessness was quickly converted to a limitless determination.
Being two highly resourceful people with a vast contact
network, as well as academic and medical backgrounds, we
embarked on an exhaustive national search for the best treatment
this country had to offer (or the world for that matter,
for there were no boundaries when it came to saving the
dog we loved so dearly).
The culmination of this comprehensive and what felt like
a desperately intensive search was The Animal Cancer Foundation,
which almost immediately far surpassed our very high expectations.
To our great relief, there existed an organization that
believed these beloved members of our families deserved
an optimal chance for survival. In addition, we readily
understood that cutting-edge and progressive treatment of
animal cancer would certainly foster cancer treatment advances
in humans, as well. As a primary focus of our philanthropic
interests had already involved the advancement of medical
treatments and technology, ACF seemed almost too good to
be true, as it uniquely addressed our desperate desire to
help our golden retriever, but it also furthered areas in
human medicine that we were already committed to.
Juliet thus began what in our understanding was the best
treatment protocol the world had to offer. As a result,
her survival time was approximately double what conventional
treatment for lymphoma in golden retrievers would have estimated.
Additionally, not only was Juliet’s quality of life
during those years unaffected, as difficult as it is to
believe, but also the quality of our interactions with Juliet
and how we perceived her personality, actually surpassed
what it had been. For all of this, our
gratitude to the ACF is immense and our commitment immeasurable.
Although the ultimate loss of Juliet was devastating and
probably the worst loss either of us has ever experienced
in our adult lives, it only strengthened our resolve concerning
the importance of the work of the ACF and the great need
for its further support. The personal and emotional gain
that the ACF has provided us, is matched by the vision and
strength of our conviction of its ultimate contribution
to the domain of human medicine and cancer treatment.
Just one month after the loss of Juliet, during what was
already a very difficult time for us, Romeo—Juliet’s
brother, our remaining golden retriever, and the other light
of our household -- was diagnosed with a mast cell tumor.
Both of our goldens having some form of cancer seemed impossible
to believe; however, ACF made us aware that approximately
63% of golden retrievers will have some type of cancer.
As one of us is a research scientist, we are profoundly
aware of how epidemiology and prevalence research greatly
informs treatment (understanding a disease is the first
crucial step towards combating it). In addition, the ACF
immediately made us aware of an experimental medication
that bettered the prognosis for Romeo by decreasing the
likelihood of a recurrence once the tumor was removed.
Once again, we were suddenly acutely aware of the contributions
of the ACF and our gratitude was overwhelming. Of particular
importance, our personal experience once again further highlighted
the unique potential impact the ACF could have both on animal
and human cancer. The progressive vision and preliminary
contributions of the ACF are consistent with our interest
in forwarding medical treatments in the care of animals
as well as humans and has certainly invaluably contributed
to the wonderful care and prognosis of both of our beloved
animals. Thus, as loving owners of two goldens, and people
quite dedicated to the advancement of science and medical
care, we are well-aware of why support for the visionary
approach of the ACF is so greatly warranted.